AIM-HI Accelerator Fund shared a post on LinkedIn:
“Portfolio company spotlight: TellBio’s TellDx platform just cleared a major milestone.
A new study published in Cancer Discovery shows that TellDx can predict which small cell lung cancer patients are most likely to respond to tarlatamab, a DLL3-targeting therapy, before treatment even begins.
The key: analyzing circulating tumor cells directly from a blood draw, no tissue biopsy required.
This matters because small-cell lung cancer is aggressive, treatment options are limited, and until now, clinicians had no reliable way to know in advance whether a patient would benefit from emerging targeted therapies. This research changes that.
AIM-HI portfolio company TellBio is turning liquid biopsy technology into real, actionable decisions for patients and their care teams. That is exactly the kind of impact we exist to fund.
Congratulations to the TellBio team and collaborators at Massachusetts General Hospital and Harvard Medical School.”
Other articles about AIM-HI Accelerator Fund on OncoDaily.